DEALS
最新交易
中伦代表再鼎医药在纳斯达克上市
中伦代表再鼎医药在纳斯达克上市
2017年9月22日，再鼎医药有限公司（股票代码：ZLAB）宣布完成首次公开发行美国存托股份并在纳斯达克全球市场上市；在承销商完全行使超额配售权后，本次发行募资总额约1.725亿美元。摩根大通、花旗集团和Leerink Partners担任本次发行的联席账簿管理人。
再鼎医药是一家总部位于上海的创新生物医药公司，致力于专有疗法的发现或许可、开发和商业化应用，以解决包括肿瘤、自身免疫、传染性疾病等在内领域的中国市场上大量未满足的医疗需求。
中伦律师事务所在本次发行中担任发行人再鼎医药的中国法律顾问。中伦律师团队由合伙人赵靖、贾海波和程芳负责，还包括律师郑泽坤、张琳竺和章舒熳等。
On September 22, 2017, Zai Lab Limited (Nasdaq: ZLAB) announced the closing of its initial public offering of American depositary shares, which have been listed on the Nasdaq Global Market, raising gross proceeds of approximately US$172.5 million upon the underwriters’ full exercise of the over-allotment option. J.P. Morgan, Citigroup and Leerink Partners acted as joint book-running managers for the offering.
Zai Lab is an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases.
Zhong Lun Law Firm acted as Zai Lab’s PRC legal counsel in the offering. The legal team from Zhong Lun was led by Anthony Zhao, William Jia and Helen Cheng, and included Roy Zheng, Lindsay Zhang and Shuman Zhang, etc.
